JEVTANA cabazitaxel

Drug Class

Microtubule inhibitor

Mechanism

Binds to tubulin and promotes its assembly into microtubules while preventing disassembly, leading to mitotic block and tumor cell apoptosis.

Approved Indication

Metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen (in combination with prednisone), per its FDA approval.

What This Means For Patients

Jevtana is an intravenous chemotherapy drug used in combination with steroids for patients with advanced prostate cancer that has progressed despite treatment with docetaxel. It disrupts the internal structure of cancer cells, and is available for patient access in Boao Lecheng.

Regulatory Approvals

• FDA — approved (2010) — label

Pivotal Clinical Evidence

• TROPIC — de Bono et al., Lancet 2010 (NCT00441831) — DOI

Sources

• https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-cabazitaxel-metastatic-castration-resistant-prostate-cancer
• https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/201023lbl.pdf